CardioGenics Holdings Inc. Announces Further Update Regarding Status of Merck & Co., Inc. Agreement

MISSISSAUGA, Ontario, March 10 /PRNewswire-FirstCall/ -- CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the IVD segment of the Point-Of-Care (POC) diagnostic market, announced today a further update regarding the status of its agreement with Merck Chimie s.a.s. (“Merck Chimie”).

MORE ON THIS TOPIC